NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Lung cancer (non-small-cell, first line) - gefitinib - NICE TAG TA192

Lung cancer (non-small-cell, first line) - gefitinib - NICE TAG TA192

1.1 Gefitinib is recommended as an option for the first-line treatment of people with locally advanced or metastatic non-small-cell lung cancer (NSCLC) if:

  • they test positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and

  • the manufacturer provides gefitinib at the fixed price agreed under the patient access scheme.

https://www.nice.org.uk/guidance/TA192

Site by Devopa
© Copyright 2019 NHS. All rights reserved.